drugset / Trial / NCT01951105
Effect of L-dopa In Subacute Back Pain Population
Phase 4
Completed
72 enrolled
Northwestern University
National Institute of Dental and Craniofacial Research (NIDCR) · collabNational Institutes of Health (NIH) · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
This study aims to determine if early treatment with Carbidopa/Levodopa and Naproxen in individuals with sub-acute back pain (SBP) is associated with changes in blocking transition to chronic back pain (CBP).
Timeline
- Start
- 2015-02-24
- Primary completion
- 2017-09-25
- Completion
- 2017-09-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Carbidopa | Unknown | 12.5 mg | Oral |
| Comparator | Carbidopa | Unknown | 25 mg | Oral |
| Comparator | Carbidopa | Unknown | 50 mg | Oral |
| Comparator | Levodopa | Small molecule | 50 mg | Oral |
| Comparator | Levodopa | Small molecule | 100 mg | Oral |
| Comparator | Levodopa | Small molecule | 200 mg | Oral |
| Comparator | Naproxen | Small molecule | 250 mg | Oral |